BIOVIE INC.

Listed Company

BIVICIK 0001580149NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaFY ends Jun 30

Period

FY 2025

Revenue

—

Net Income

$-17.54M

Total Assets

$21.56M

Equity

$19.01M

Shares Out

7.54M

Op. Cash Flow

$-19.03M

Business

BIOVIE INC. is a clinical-stage biopharmaceutical company developing drug therapies for neurological and neurodegenerative disorders and for advanced liver disease. It develops bezisterim (NE3107), an oral blood‑brain‑barrier‑permeable anti‑inflammatory insulin‑sensitizer for Alzheimer’s, Parkinson’s and long COVID neurological symptoms, and BIV201, a room‑temperature stable continuous‑infusion terlipressin formulation for ascites. Its business is organized into neurodegenerative disease and liver cirrhosis programs, with associated clinical development and intellectual property activities. It conducts clinical trials and regulatory interactions in the United States and pursues patent protection internationally.

Summary from filing dated 2025-08-15

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Amortization of intangible assets	229,377	229,377	229,377	229,377	229,377
Research and development expenses	9	23	33	17	3
Selling, general and administrative expenses	9	9	12	10	5
TOTAL OPERATING EXPENSES	18	32	45	27	138
LOSS FROM OPERATIONS	−18	−32	−45	−27	−138
Change in fair value of derivative liabilities	−3,771	−2	1	−3	−8
Interest expense	332,720	3	—	—	—
Interest income	−853,029	−1	−562,264	−44,080	−21,971
TOTAL OTHER INCOME , NET	−524,080	−59,052	5	—	—
NET LOSS	−18	−32	−50	−26	—
Deemed dividend related to ratchet adjustment to warrants	369,465	886,423	—	—	—
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	−18	−33	−50	−26	−184
- Basic (per share)	−12.12	−73.05	−15.47	−1.06	−14.82
- Diluted (per share)	−12.12	−73.05	−15.47	−1.06	−14.82
- Basic (shares)	1	451,853	3	25	12
- Diluted (shares)	1	451,853	3	25	12
Reclassification of unrealized gains on available-for-sale investments upon settlement	—	−176,591	—	—	—
Total other comprehensive loss	—	−176,591	176,591	—	—
Comprehensive loss	−18	−33	−50	−26	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2024 2024-01-31	FY 2023 2023-06-30	FY 2022 2022-06-30
Cash and cash equivalents	18	24	—	19	19
Grant receivable	2	—	—	—	—
Prepaid and other current assets	1	204,392	—	—	—
Total current assets	21	24	—	34	19
Operating lease right-of-use asset, net	339,653	406,726	56,909	80,789	118,254
Intangible assets, net	178,341	407,718	—	637,095	866,472
Goodwill	345,711	345,711	—	345,711	345,711
TOTAL ASSETS	22	25	—	35	20
Accounts payable and accrued expenses	2	4	—	3	2
Current portion of operating lease liability	74,464	60,343	—	44,909	38,884
Current portion of notes payable, net of financing cost, unearned premium and discount of $701,210 at June 30, 2024	—	6	—	9	—
Warrant liability	—	3,771	—	894,280	194,531
Total current liabilities	2	9	—	14	4
Operating lease liability, net of current portion	275,430	349,894	—	42,505	87,414
TOTAL LIABILITIES	3	10	—	20	16
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding	—	—	—	—	—
Common stock, $0.0001 par value; 800,000,000 shares authorized at June 30, 2025 and June 30, 2024; 1,917,061 shares issued of which 1,914,224 shares are outstanding at June 30, 2025; and 621,641 shares issued of which 619,008 shares outstanding at June 30, 2024	7,476	6,229	—	3,643	2,496
Additional paid in capital	371	350	—	316	255
Accumulated deficit	−352	−334	—	−301	−251
Treasury stock	−29	−27	—	−2	—
Total stockholders' equity	19	16	—	15	4
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	22	25	—	35	20

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Stock based compensation - restricted stock units and restricted shares	1	2	2	386,208	—
Stock based compensation expense - stock options	1	3	4	6	—
Stock based compensation expense - issuance of common stock for services rendered	73,680	72,900	—	—	—
Amortization of financing costs	11,820	108,751	170,219	99,295	—
Accretion of unearned loan discount	111,212	1	2	—	—
Accretion of loan premium	25,758	236,970	421,994	165,278	—
Realized gain on maturity of available-for sale	—	−223,865	—	—	—
Non-cash lease expense from right-of-use assets	67,073	49,346	37,465	—	—
Gain on termination of operating lease	—	−5,215	—	—	—
Change in fair value of derivative liabilities	−3,771	−2	1	−3	−8
Grant receivable	−2	—	—	—	—
Prepaid and other current assets	−845,505	−101,866	39,915	−48,954	—
Accounts payable and accrued expenses	−1	110,653	1	1	−262,832
Operating lease liabilities	−60,343	−47,245	−38,884	—	—
Other current liabilities	—	−48,385	−1	1	—
Net cash used in operating activities	−19	−28	−40	−19	−10
Proceeds from U.S. Treasury Bills (available-for-sale)	—	15	−14	—	—
Net cash provided by investing activities	—	15	−14	—	—
Net proceeds from issuance of common stock	16	28	49	19	16
Proceeds from exercise of warrants	3	−10	—	—	—
Payment of loan premium	−850,000	—	—	—	—
Payments of note payable	−5	—	—	—	—
Net cash provided by financing activities	13	18	55	33	15
Net change in cash and cash equivalents	−6	4	819,167	14	4
Cash paid for interest	183,930	2	2	964,241	22,180
Right of use assets obtained in exchange for lease obligations	—	432,192	—	130,039	—
Deemed dividend for ratchet adjustment to warrants	369,465	886,423	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro